CPSE:ONXEO

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Onxeo SA, a biotechnology company, develops drugs for the treatment of orphan oncology diseases worldwide.


Snowflake Analysis

Imperfect balance sheet and overvalued.


Similar Companies

Share Price & News

How has Onxeo's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ONXEO's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

1.4%

ONXEO

0.3%

DK Biotechs

3.7%

DK Market


1 Year Return

-37.5%

ONXEO

29.4%

DK Biotechs

21.4%

DK Market

Return vs Industry: ONXEO underperformed the Danish Biotechs industry which returned 27.6% over the past year.

Return vs Market: ONXEO underperformed the Danish Market which returned 19.1% over the past year.


Shareholder returns

ONXEOIndustryMarket
7 Day1.4%0.3%3.7%
30 Day5.8%6.7%6.5%
90 Day-6.3%3.8%3.4%
1 Year-37.5%-37.5%30.4%29.4%23.8%21.4%
3 Year-89.0%-89.0%29.2%26.4%45.6%33.5%
5 Year-90.9%-90.9%57.4%52.1%48.7%29.9%

Price Volatility Vs. Market

How volatile is Onxeo's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Onxeo undervalued compared to its fair value and its price relative to the market?

1.73x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ONXEO's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ONXEO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ONXEO is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: ONXEO is unprofitable, so we can't compare its PE Ratio to the Danish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ONXEO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ONXEO is good value based on its PB Ratio (1.7x) compared to the XE Biotechs industry average (4.4x).


Next Steps

Future Growth

How is Onxeo forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

32.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if ONXEO's forecast earnings growth is above the savings rate (0.3%).

Earnings vs Market: Insufficient data to determine if ONXEO's earnings are forecast to grow faster than the Danish market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if ONXEO's revenue is forecast to grow faster than the Danish market.

High Growth Revenue: Insufficient data to determine if ONXEO's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ONXEO's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Onxeo performed over the past 5 years?

-16.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ONXEO is currently unprofitable.

Growing Profit Margin: ONXEO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ONXEO is unprofitable, and losses have increased over the past 5 years at a rate of -16% per year.

Accelerating Growth: Unable to compare ONXEO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ONXEO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.5%).


Return on Equity

High ROE: ONXEO has a negative Return on Equity (-196.13%), as it is currently unprofitable.


Next Steps

Financial Health

How is Onxeo's financial position?


Financial Position Analysis

Short Term Liabilities: ONXEO's short term assets (€11.3M) exceed its short term liabilities (€6.2M).

Long Term Liabilities: ONXEO's short term assets (€11.3M) do not cover its long term liabilities (€14.2M).


Debt to Equity History and Analysis

Debt Level: ONXEO's debt to equity ratio (35.7%) is considered satisfactory.

Reducing Debt: ONXEO's debt to equity ratio has increased from 1.3% to 35.7% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ONXEO has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ONXEO has less than a year of cash runway if free cash flow continues to grow at historical rates of 2.4% each year.


Next Steps

Dividend

What is Onxeo's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ONXEO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ONXEO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ONXEO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ONXEO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ONXEO's dividend in 3 years as they are not forecast to pay a notable one for the Danish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.7yrs

Average management tenure


CEO

Judith Greciet (51yo)

8.92yrs

Tenure

€455,498

Compensation

Ms. Judith Greciet, Ph.D., Pharmacy, has been the Chief Executive Officer of Onxeo SA (alternate name BioAlliance Pharma) since June 29, 2011. Ms. Greciet served as the Chief Operations Officer - Operation ...


CEO Compensation Analysis

Compensation vs Market: Judith's total compensation ($USD496.19K) is about average for companies of similar size in the Danish market ($USD419.38K).

Compensation vs Earnings: Judith's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Judith Greciet
CEO & Director8.92yrs€455.50k0.36% 853.7k
Nicolas Fellmann
CFO & Administrative and Finance Director13.5yrsno datano data
Françoise Bono
Chief Scientific Officer3.17yrsno datano data
Audrey Legentil-Dumery
Director of Human Resources5.25yrsno datano data
Michel Forest
Chief Pharmacist & Quality Assurance Directorno datano datano data
Philippe Maitre
Chief of US Operations & Executive VP4.17yrsno datano data
Olivier de Beaumont
Chief Medical Officer3.17yrsno datano data

4.7yrs

Average Tenure

51yo

Average Age

Experienced Management: ONXEO's management team is considered experienced (4.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Judith Greciet
CEO & Director8.92yrs€455.50k0.36% 853.7k
Thomas Hofstaetter
Independent Director8yrs€10.20kno data
Jean-Pierre Kinet
Independent Director4.08yrs€8.70kno data
Tomas Lindahl
Chairman of Scientific Advisory Board2.5yrsno datano data
Christine Garnier
Independent Director3.08yrs€9.20kno data
Marie Dutreix
Member of Scientific Advisory Board2.5yrsno datano data
Jean-Pierre Bizzari
Independent Director4.08yrs€7.70kno data
Nicolas Trebouta
Representative Director8.92yrsno data0.062% 147.4k
Danièle Guyot-Caparros
Independent Chairman1yr€26.35kno data
Elvira Urgoiti
Independent Director3.08yrs€9.70kno data

3.6yrs

Average Tenure

60.5yo

Average Age

Experienced Board: ONXEO's board of directors are considered experienced (3.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.8%.


Top Shareholders

Company Information

Onxeo SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Onxeo SA
  • Ticker: ONXEO
  • Exchange: CPSE
  • Founded: 1997
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €31.974m
  • Listing Market Cap: €238.442m
  • Shares outstanding: 65.52m
  • Website: https://www.onxeo.com

Number of Employees


Location

  • Onxeo SA
  • 49, boulevard du Général Martial Valin
  • Paris
  • Ile-de-France
  • 75015
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ONXEOENXTPA (Euronext Paris)YesOrdinary SharesFREURDec 2005
C4XDB (Deutsche Boerse AG)YesOrdinary SharesDEEURDec 2005
0NWKLSE (London Stock Exchange)YesOrdinary SharesGBEURDec 2005
OXNX.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDDec 2005
ONXEOCPSE (OMX Nordic Exchange Copenhagen)YesOrdinary SharesDKDKKDec 2005
ONXEOPBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBEURDec 2005

Biography

Onxeo SA, a biotechnology company, develops drugs for the treatment of orphan oncology diseases worldwide. The company offers Beleodaq for the treatment of relapsed or refractory peripheral T-cell lymphoma. It also develops AsiDNA, which is in clinical development stage for the treatment of metastatic melanoma; and Validive, which completed Phase II clinical trial for the treatment of serious mucositis in patients treated for a head and neck cancer. Onxeo SA has a collaboration and licensing agreement with Spectrum Pharmaceuticals for the development of Beleodaq; a license agreement with Monopar Therapeutics Inc. to develop Validive; and clinical research agreement with Gustave Roussy to conduct clinical trial of AsiDNA for the treatment of relapsed ovarian cancer. The company was formerly known as BioAlliance Pharma SA and changed its name to Onxeo SA in July 2014. Onxeo SA was founded in 1997 and is based in Paris, France. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/05/25 00:16
End of Day Share Price2020/05/20 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.